These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 23820059)

  • 61. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
    Hong SK; Oh JJ; Lee S; Lee HM; Byun SS; Choe G; Lee SE
    Prostate; 2012 Aug; 72(11):1187-92. PubMed ID: 22161951
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
    Fradet V; Toren P; Nguile-Makao M; Lodde M; Lévesque J; Léger C; Caron A; Bergeron A; Ben-Zvi T; Lacombe L; Pouliot F; Tiguert R; Dujardin T; Fradet Y
    BJU Int; 2018 Mar; 121(3):399-404. PubMed ID: 28972698
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The prognostic significance of perineural invasion and race in men considering active surveillance.
    Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
    Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Is race a positive predictor of cancer on repeat prostate biopsy?
    Yanke BV; Salzhauer EW; Colon I
    J Urol; 2006 Sep; 176(3):1114-7. PubMed ID: 16890704
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF; Regan MM; Olumi AF; DeWolf WC
    J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
    Palanisamy N; Tsodikov A; Yan W; Suleman K; Rittmaster R; Lucia SM; Chinnaiyan AM; Fleshner N; Kunju LP
    Urol Oncol; 2015 Mar; 33(3):108.e5-13. PubMed ID: 25175425
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
    Fowke JH; Howard L; Andriole GL; Freedland SJ
    Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.
    Roehrborn CG; Wilson TH; Black LK
    J Urol; 2012 May; 187(5):1732-8. PubMed ID: 22425127
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
    Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
    BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging.
    Robertson NL; Moore CM; Ambler G; Bott SR; Freeman A; Gambarota G; Jameson C; Mitra AV; Whitcher B; Winkler M; Kirkham A; Allen C; Emberton M
    Contemp Clin Trials; 2013 Jan; 34(1):80-9. PubMed ID: 23085153
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.